CardioBrief: At Last, a Positive Diabetes Drug Outcomes Trial?
(MedPage Today) -- Study of SGLT2 inhibitor empagliflozin may be the first to show cardiovascular benefit
Source: MedPage Today Neurology - Category: Neurology Source Type: news
More News: Brain | Cardiology | Cardiovascular | Diabetes | Empagliflozin | Endocrinology | Heart | Jardiance | Neurology | SGLT2 Inhibitors | Study